1. 1133PDA phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC). (23rd October 2018) Authors: Hidalgo, M; Epelbaum, R; Wolpin, B M; Stemmer, S M; Geva, R; Golan, T; Borazanci, E; Borad, M; Pedersen, K S; Park, J O; Ramirez, R; Peled, A; Lustig, T M; Bohana Kashtan, O; Rosenfeld, O; Sorani, E; Schlienger, K; Vainstein Haras, A; Von Hoff, D D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. O-021Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164. (20th June 2018) Authors: Le, D; Kavan, P; Kim, T; Burge, M; Van Cutsem, E; Hara, H; Boland, P; Van Laethem, J; Geva, R; Taniguchi, H; Crocenzi, T; Sharma, M; Atreya, C; Diaz, L; Liang, L; Marinello, P; Dai, T; O'Neill, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗